Bayer and Peking University establish new research center for translational research and drug discovery in Beijing

BayerBayer HealthCare and Peking University (PKU), Beijing, China, have signed a comprehensive collaboration agreement on a three-year strategic partnership to promote translational research for drug discovery. Under this agreement, the two partners will establish a joint research center at Peking University under the name Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery (BPC/TRDD).

"Strategic alliances with international innovation partners from industry and academia are an essential element of our R&D strategy and complement our own research capabilities," said Prof. Dr. Andreas Busch. "The establishment of this research collaboration with Peking University also demonstrates Bayer's ongoing commitment to China as an important location in our innovation strategy. We are excited about the opportunity to collaborate with the excellent scientists at Peking University."

The collaboration will focus on applying basic research to drug discovery in the therapeutic areas of cardiology, oncology, hematology, and gynecological therapy, as well as technological research along the drug-discovery and -development value chain. Through this collaboration, scientists at PKU and BHC will be able to work together on the discovery of new medicines and contribute to the innovation landscape in China.

"The open innovation model chosen for this industry/university partnership is an excellent way to combine the academic creativity at Peking University with Bayer HealthCare's industrial drug development experience to accelerate today’s drug-discovery processes," said Prof. Dongmin Chen, Dean of the School of Innovation and Entrepreneurship and Director of the Office of Science and Technology Development at Peking University.

The Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery will serve as a platform enabling scientists in life-sciences-related schools - such as the School of Life Sciences & Institute of Molecular Medicine and the School of Chemical Biology & Biotechnology and other affiliations at Peking University - to collaborate with scientists at Bayer HealthCare Global Drug Discovery.

"The broad spectrum of basic research expertise at PKU perfectly complements Bayer's experience and long-term commitment in novel drug discovery," said Prof. Hong Wu, Dean of the School of Life Sciences of Peking University and a Fellow of the American Association for the Advancement of Science, who will - together with Dr. Jing-Shan "Jennifer" Hu, Vice President and Head of Innovation Center China at Bayer HealthCare - be responsible for directing the research activities at the BPC/TRDD. "We are looking forward to collaborating with our colleagues at Bayer to improve human health through translational research."

As part of the agreement with Peking University, Bayer HealthCare will provide funding for collaborative research projects. In addition, Bayer will sponsor a Bayer Professorship and Bayer Investigator Awards to promote and reward scientific excellence, important contributions to life sciences, and research that is beneficial to drug discovery, especially in the fields of Bayer HealthCare's core therapeutic areas.

The strategic partnership with Peking University further underlines Bayer HealthCare's ongoing commitment to China as an important location in its innovation strategy. Bayer HealthCare's Innovation Center China was established as early as 2009 as part of its R&D Center China to strengthen the company's global research-and-development capabilities and to include the clinical profiles and medical needs of Asian patients early on in its drug development activities.

About Peking University
Peking University (PKU) is the first national comprehensive university in China, established in 1898. It has become one of the top comprehensive national key universities in China, consisting of 41 schools with disciplines in natural sciences, humanities, social sciences, technological sciences, information science & engineering, medical sciences, etc. Currently, there are more than 8,600 faculty and staff members, over 30,000 undergraduate and graduate students, and over 271 institutes and research centers at Peking University. Some of its strong disciplines relevant to drug discovery include life sciences, chemistry, medical and pharmaceutical sciences, as well as 8 affiliated hospitals. Nowadays, Peking University has become the cradle for high-caliber and creative talents, a frontier of research and innovation, as well as a bridge for international exchanges in China. In the past few years, it has hosted the visits of the government heads of nearly 30 countries and states and nearly 300 chancellors of world-renown universities. It has established exchange programs with more than 240 universities from over 50 countries.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 54,900 employees (Dec 31, 2012) and is represented in more than 100 countries.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...